DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed Inc. (NASDAQ: ABMD - News), a leading provider of breakthrough heart support technologies, today announced Symphony™, a new synchronized minimally invasive implantable cardiac assist device, designed to treat chronic patients with moderate heart failure by improving patient hemodynamics, and potentially improving quality of life. The device is designed with the primary goal of stabilizing the progression of heart failure and/or recovering/remodeling the heart. Prior to this, no current implantable cardiac assist device had been designed for heart recovery or remodeling.
